Issue

Vol. 12 (2020)

A Review on Nano-Based Drug Delivery System for Cancer Chemoimmunotherapy

https://doi.org/10.1007/s40820-020-00482-6
Weiwei Mu
Department of Pharmaceutics, Key Laboratory of Chemical Biology (Ministry of Education), School of Pharmaceutical Sciences, Cheeloo College of Medicine, Shandong University, 44 Wenhuaxi Road, Jinan 250012, People’s Republic of China
Qihui Chu
Department of Pharmaceutics, Key Laboratory of Chemical Biology (Ministry of Education), School of Pharmaceutical Sciences, Cheeloo College of Medicine, Shandong University, 44 Wenhuaxi Road, Jinan 250012, People’s Republic of China
Yongjun Liu
Department of Pharmaceutics, Key Laboratory of Chemical Biology (Ministry of Education), School of Pharmaceutical Sciences, Cheeloo College of Medicine, Shandong University, 44 Wenhuaxi Road, Jinan 250012, People’s Republic of China
Na Zhang
Department of Pharmaceutics, Key Laboratory of Chemical Biology (Ministry of Education), School of Pharmaceutical Sciences, Cheeloo College of Medicine, Shandong University, 44 Wenhuaxi Road, Jinan 250012, People’s Republic of China

Corresponding Author: Na Zhang

zhangnancy9@sdu.edu.cn

Nano-Micro Letters, Vol. 12 (2020), Article Number: 142

Abstract

Although notable progress has been made on novel cancer treatments, the overall survival rate and therapeutic effects are still unsatisfactory for cancer patients. Chemoimmunotherapy, combining chemotherapeutics and immunotherapeutic drugs, has emerged as a promising approach for cancer treatment, with the advantages of cooperating two kinds of treatment mechanism, reducing the dosage of the drug and enhancing therapeutic effect. Moreover, nano-based drug delivery system (NDDS) was applied to encapsulate chemotherapeutic agents and exhibited outstanding properties such as targeted delivery, tumor microenvironment response and site-specific release. Several nanocarriers have been approved in clinical cancer chemotherapy and showed significant improvement in therapeutic efficiency compared with traditional formulations, such as liposomes (Doxil®, Lipusu®), nanoparticles (Abraxane®) and micelles (Genexol-PM®). The applications of NDDS to chemoimmunotherapy would be a powerful strategy for future cancer treatment, which could greatly enhance the therapeutic efficacy, reduce the side effects and optimize the clinical outcomes of cancer patients. Herein, the current approaches of cancer immunotherapy and chemoimmunotherapy were discussed, and recent advances of NDDS applied for chemoimmunotherapy were further reviewed.


Highlights:


1 The current approaches of cancer immunotherapy were summarized.
2 The prospects in combination of chemotherapy and immunotherapy were discussed.
3 The recent progress of nano-based drug delivery systems applied for cancer chemoimmunotherapy was further categorized and reviewed.

Keywords

Cancer therapy Chemotherapy Immunotherapy Chemoimmunotherapy Nano-based drug delivery system
Mu, Weiwei, Qihui Chu, Yongjun Liu, and Na Zhang. 2020. “A Review on Nano-Based Drug Delivery System for Cancer Chemoimmunotherapy”. Nano-Micro Letters 12 (July):142. https://doi.org/10.1007/s40820-020-00482-6.
Download Citation
Endnote/Zotero/Mendeley (RIS)
BibTeX
References
  1. R.L. Siegel, K.D. Miller, A. Jemal, Cancer statistics, 2016. CA Cancer J. Clin. 66, 7–30 (2016). https://doi.org/10.3322/caac.21332
  2. F. Bray, J. Ferlay, I. Soerjomataram, R.L. Siegel, L.A. Torre, A. Jemal, Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 68(6), 394–424 (2018). https://doi.org/10.3322/caac.21492
  3. A.B. Miller, B. Hoogstraten, M. Staquet, A. Winkler, Reporting results of cancer treatment. Cancer 47, 207–214 (1981). https://doi.org/10.1002/1097-0142(19810101)47:1%3c207:AID-CNCR2820470134%3e3.0.CO;2-6
  4. T.A. Waldmann, Immunotherapy: past, present and future. Nat. Med. 9, 269–277 (2003). https://doi.org/10.1038/nm0303-269
  5. M. McNutt, Cancer immunotherapy. Science 342, 1417 (2013). https://doi.org/10.1126/science.1249481
  6. T. Jiang, C. Zhou, The past, present and future of immunotherapy against tumor. Transl. Lung Cancer R 4, 253–264 (2015). https://doi.org/10.3978/j.issn.2218-6751.2015.01.06
  7. K. Esfahani, L. Roudaia, N. Buhlaiga, S.V. Del Rincon, N. Papneja, W.H. Miller Jr., A review of cancer immunotherapy: from the past, to the present, to the future. Curr. Oncol. 27, S87–S97 (2020). https://doi.org/10.3747/co.27.5223
  8. I. Mellman, G. Coukos, G. Dranoff, Cancer immunotherapy comes of age. Nature 480, 480–489 (2011). https://doi.org/10.1038/nature10673
  9. D.M. Pardoll, The blockade of immune checkpoints in cancer immunotherapy. Nat. Rev. Cancer 12, 252–264 (2012). https://doi.org/10.1038/nrc3239
  10. Y. Li, F. Li, F. Jiang, X. Lv, R. Zhang, A. Lu, G. Zhang, A mini-review for cancer immunotherapy: molecular understanding of PD-1/PD-L1 pathway & translational blockade of immune checkpoints. Int. J. Mol. Sci. 17(7), 1151 (2016). https://doi.org/10.3390/ijms17071151
  11. A.C. Anderson, N. Joller, V.K. Kuchroo, Lag-3, Tim-3, and TIGIT: co-inhibitory receptors with specialized functions in immune regulation. Immunity 44, 989–1004 (2016). https://doi.org/10.1016/j.immuni.2016.05.001
  12. C.R. Parish, Cancer immunotherapy: the past, the present and the future. Immunol. Cell Biol. 81, 106–113 (2003). https://doi.org/10.1046/j.0818-9641.2003.01151.x
  13. G. Chen, L.A. Emens, Chemoimmunotherapy: reengineering tumor immunity. Cancer Immunol. Immun. 62, 203–216 (2013). https://doi.org/10.1007/s00262-012-1388-0
  14. A.K. Nowak, W.J. Lesterhuis, Chemoimmunotherapy: still waiting for the magic to happen. Lancet Oncol. 15, 780–781 (2014). https://doi.org/10.1016/S1470-2045(14)70267-0
  15. D.M. Francis, S.N. Thomas, Progress and opportunities for enhancing the delivery and efficacy of checkpoint inhibitors for cancer immunotherapy. Adv. Drug Deliv. Rev. 114, 33–42 (2017). https://doi.org/10.1016/j.addr.2017.04.011
  16. A.M. Cook, W.J. Lesterhuis, A.K. Nowak, R.A. Lake, Chemotherapy and immunotherapy: mapping the road ahead. Curr. Opin. Immunol. 39, 23–29 (2016). https://doi.org/10.1016/j.coi.2015.12.003
  17. L. Galluzzi, L. Senovilla, L. Zitvogel, G. Kroemer, The secret ally: immunostimulation by anticancer drugs. Nat. Rev. Drug Discov. 11, 215–233 (2012). https://doi.org/10.1038/nrd3626
  18. Y.L. Chen, M.C. Chang, W.F. Cheng, Metronomic chemotherapy and immunotherapy in cancer treatment. Cancer Lett. 400, 282–292 (2017). https://doi.org/10.1016/j.canlet.2017.01.040
  19. S. Goel, M.J. DeCristo, A.C. Watt, H. BrinJones, J. Sceneay et al., CDK4/6 inhibition triggers anti-tumour immunity. Nature 548, 471–475 (2017). https://doi.org/10.1038/nature23465
  20. N.K. Egilmez, J.L. Harden, R.B. Rowswell-Turner, Chemoimmunotherapy as long-term maintenance therapy for cancer. Oncoimmunology 1(4), 563–565 (2012). https://doi.org/10.4161/onci.19369
  21. C. He, Z. Tang, H. Tian, X. Chen, Co-delivery of chemotherapeutics and proteins for synergistic therapy. Adv. Drug Deliv. Rev. 98, 64–76 (2016). https://doi.org/10.1016/j.addr.2015.10.021
  22. C.M. Hu, S. Aryal, L. Zhang, Nanoparticle-assisted combination therapies for effective cancer treatment. Ther. Deliv. 1, 323–334 (2010). https://doi.org/10.4155/tde.10.13
  23. C.G. Da Silva, F. Rueda, C.W. Lowik, F. Ossendorp, L.J. Cruz, Combinatorial prospects of nano-targeted chemoimmunotherapy. Biomaterials 83, 308–320 (2016). https://doi.org/10.1016/j.biomaterials.2016.01.006
  24. T. Shao, X. Li, J. Ge, Target drug delivery system as a new scarring modulation after glaucoma filtration surgery. Diagn. Pathol. 6, 64 (2011). https://doi.org/10.1186/1746-1596-6-64
  25. D.S. Chen, I. Mellman, Oncology meets immunology: the cancer-immunity cycle. Immunity 39, 1–10 (2013). https://doi.org/10.1016/j.immuni.2013.07.012
  26. C.H. Kapadia, J.L. Perry, S. Tian, J.C. Luft, J.M. DeSimone, Nanoparticulate immunotherapy for cancer. J. Control. Release 219, 167–180 (2015). https://doi.org/10.1016/j.jconrel.2015.09.062
  27. B.D. Cheson, J.P. Leonard, Monoclonal antibody therapy for B-cell non-Hodgkin’s lymphoma. New Engl. J. Med. 359, 613–626 (2008). https://doi.org/10.1056/NEJMra0708875
  28. A.M. Scott, J.D. Wolchok, L.J. Old, Antibody therapy of cancer. Nature reviews. Cancer 12, 278–287 (2012). https://doi.org/10.1038/nrc3236
  29. P. Sharma, J.P. Allison, The future of immune checkpoint therapy. Science 348, 56–61 (2015). https://doi.org/10.1126/science.aaa8172
  30. A.W. Hahn, D.M. Gill, S.K. Pal, N. Agarwal, The future of immune checkpoint cancer therapy after PD-1 and CTLA-4. Immunotherapy 9, 681–692 (2017). https://doi.org/10.2217/imt-2017-0024
  31. C. Robert, L. Thomas, I. Bondarenko, S. O’Day, J. Weber et al., Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. New Engl. J. Med. 364, 2517–2526 (2011). https://doi.org/10.1056/NEJMoa1104621
  32. C. Kyi, M.A. Postow, Checkpoint blocking antibodies in cancer immunotherapy. FEBS Lett. 588, 368–376 (2014). https://doi.org/10.1016/j.febslet.2013.10.015
  33. A. Markham, S. Duggan, Cemiplimab: first global approval. Drugs 78, 1841–1846 (2018). https://doi.org/10.1007/s40265-018-1012-5
  34. E.S. Kim, Avelumab: first global approval. Drugs 77, 929–937 (2017). https://doi.org/10.1007/s40265-017-0749-6
  35. Y.Y. Syed, Durvalumab: first global approval. Drugs 77, 1369–1376 (2017). https://doi.org/10.1007/s40265-017-0782-5
  36. M.A. Postow, J. Chesney, A.C. Pavlick, C. Robert, K. Grossmann et al., Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. New Engl. J. Med. 372, 2006–2017 (2015). https://doi.org/10.1056/NEJMoa1414428
  37. R. Sankaranarayanan, HPV vaccination: the most pragmatic cervical cancer primary prevention strategy. Int. J. Gynecol. Obstet. 131, S33–S35 (2015). https://doi.org/10.1016/j.ijgo.2015.02.014
  38. I. Melero, G. Gaudemack, W. Gerritsen, C. Huber, G. Parmiani et al., Therapeutic vaccines for cancer: an overview of clinical trials. Nat. Rev. Clin. Oncol. 11, 509–524 (2014). https://doi.org/10.1038/nrclinonc.2014.111
  39. J. Schlom, Therapeutic cancer vaccines: current status and moving forward. Jnci-J. Natl. Cancer I 104, 599–613 (2012). https://doi.org/10.1093/jnci/djs033
  40. O.J. Finn, S.N. Khleif, R.B. Herberman, The FDA guidance on therapeutic cancer vaccines: the need for revision to include preventive cancer vaccines or for a new guidance dedicated to them. Cancer Prev. Res. 8, 1011–1016 (2015). https://doi.org/10.1158/1940-6207.CAPR-15-0234
  41. D.J. Schwartzentruber, D.H. Lawson, J.M. Richards, R.M. Conry, D.M. Miller et al., Gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma. New Engl. J. Med. 364, 2119–2127 (2011). https://doi.org/10.1056/NEJMoa1012863
  42. J.A. Sosman, C. Carrillo, W.J. Urba, L. Flaherty, M.B. Atkins et al., Three phase II cytokine working group trials of gp100 (210 M) peptide plus high-dose interleukin-2 in patients with HLA-A2-positive advanced melanoma. J. Clin. Oncol. 26, 2292–2298 (2008). https://doi.org/10.1200/Jco.2007.13.3165
  43. J. Karbach, A. Neumann, A. Atmaca, C. Wahle, K. Brand et al., Efficient in vivo priming by vaccination with recombinant NY-ESO-1 protein and CpG in antigen naive prostate cancer patients. Clin. Cancer Res. 17, 861–870 (2011). https://doi.org/10.1158/1078-0432.CCR-10-1811
  44. J. Schlom, Therapeutic cancer vaccines: current status and moving forward. J. Natl. Cancer I 104, 599–613 (2012). https://doi.org/10.1093/jnci/djs033
  45. M. Saxena, N. Bhardwaj, Turbocharging vaccines: emerging adjuvants for dendritic cell based therapeutic cancer vaccines. Curr. Opin. Immunol. 47, 35–43 (2017). https://doi.org/10.1016/j.coi.2017.06.003
  46. M. Mueller, R. Amann, T. Feger, H.G. Rammensee, The mode of action of Orf virus: a novel viral vector for therapeutic cancer vaccines. Cancer Immunol. Res. 4, 2326–6074 (2016). https://doi.org/10.1158/2326-6074.Cricimteatiaacr15-A170
  47. Y. Fujiwara, K. Okada, T. Omori, K. Sugimura, H. Miyata et al., Multiple therapeutic peptide vaccines for patients with advanced gastric cancer. Int. J. Oncol. 50, 1655–1662 (2017). https://doi.org/10.3892/ijo.2017.3955
  48. S. Mohammed, N. Bakshi, N. Chaudri, J. Akhter, M. Akhtar, Cancer vaccines: past, present, and future. Adv. Anat. Pathol. 23, 180–191 (2016). https://doi.org/10.1097/PAP.0000000000000116
  49. M.E. Dudley, S.A. Rosenberg, Adoptive cell transfer therapy. Semin. Oncol. 34, 524–531 (2007). https://doi.org/10.1053/j.seminoncol.2007.09.002
  50. M.E. Dudley, S.A. Rosenberg, Adoptive-cell-transfer therapy for the treatment of patients with cancer. Nat. Rev. Cancer 3, 666–675 (2003). https://doi.org/10.1038/nrc1167
  51. Z. Wang, Z. Wu, Y. Liu, W. Han, New development in CAR-T cell therapy. J. Hematol. Oncol. 10, 53 (2017). https://doi.org/10.1186/s13045-017-0423-1
  52. M.M. D’Aloia, I.G. Zizzari, B. Sacchetti, L. Pierelli, M. Alimandi, CAR-T cells: the long and winding road to solid tumors. Cell Death Dis. 9, 282 (2018). https://doi.org/10.1038/s41419-018-0278-6
  53. C.W. Shields, M.A. Evans, L.L.W. Wang, N. Baugh, S. Iyer et al., Cellular backpacks for macrophage immunotherapy. Sci. Adv. 6, 6579 (2020). https://doi.org/10.1126/sciadv.aaz6579
  54. G. Dranoff, Cytokines in cancer pathogenesis and cancer therapy. Nat. Rev. Cancer 4, 11–22 (2004). https://doi.org/10.1038/nrc1252
  55. A. Showalter, A. Limaye, J.L. Oyer, R. Igarashi, C. Kittipatarin, A.J. Copik, A.R. Khaled, Cytokines in immunogenic cell death: applications for cancer immunotherapy. Cytokine 97, 123–132 (2017). https://doi.org/10.1016/j.cyto.2017.05.024
  56. P. Berraondo, M.F. Sanmamed, M.C. Ochoa, I. Etxeberria, M.A. Aznar et al., Cytokines in clinical cancer immunotherapy. Br. J. Cancer 120, 6–15 (2019). https://doi.org/10.1038/s41416-018-0328-y
  57. S. Lee, K. Margolin, Cytokines in cancer immunotherapy. Cancers 3, 3856–3893 (2011). https://doi.org/10.3390/cancers3043856
  58. W. Liao, J.X. Lin, W.J. Leonard, IL-2 family cytokines: new insights into the complex roles of IL-2 as a broad regulator of T helper cell differentiation. Curr. Opin. Immunol. 23, 598–604 (2011). https://doi.org/10.1016/j.coi.2011.08.003
  59. X. Wang, Y. Lin, Tumor necrosis factor and cancer, buddies or foes? Acta Pharmacol. Sin. 29, 1275–1288 (2008). https://doi.org/10.1111/j.1745-7254.2008.00889.x
  60. A. Ashkenazi, R.C. Pai, S. Fong, S. Leung, D.A. Lawrence et al., Safety and antitumor activity of recombinant soluble Apo2 ligand. J. Clin. Invest. 104, 155–162 (1999). https://doi.org/10.1172/JCI6926
  61. A.E. Foster, K. Forrester, Y.C. Li, D.J. Gottlieb, Ex-vivo uses and applications of cytokines for adoptive immunotherapy in cancer. Curr. Pharm. Des. 10, 1207–1220 (2004). https://doi.org/10.2174/1381612043452631
  62. Y. Fan, J.J. Moon, Nanoparticle drug Ddelivery systems designed to improve cancer vaccines and immunotherapy. Vaccines 3, 662–685 (2015). https://doi.org/10.3390/vaccines3030662
  63. S.Y. Qin, Y.J. Cheng, Q. Lei, A.Q. Zhang, X.Z. Zhang, Combinational strategy for high-performance cancer chemotherapy. Biomaterials 171, 178–197 (2018). https://doi.org/10.1016/j.biomaterials.2018.04.027
  64. M. Zhang, E.G. Liu, Y.N. Cui, Y.Z. Huang, Nanotechnology-based combination therapy for overcoming multidrug-resistant cancer. Cancer Biol. Med. 14, 212–227 (2017). https://doi.org/10.20892/j.issn.2095-3941.2017.0054
  65. W. Mu, D. Jiang, S. Mu, S. Liang, Y. Liu, N. Zhang, Promoting early diagnosis and precise therapy of hepatocellular carcinoma by glypican-3-targeted synergistic chemo-photothermal theranostics. ACS Appl. Mater. Interfaces. 11, 23591–23604 (2019). https://doi.org/10.1021/acsami.9b05526
  66. C.C. Wang, L.C. Liu, H.L. Cao, W. Zhang, Intracellular GSH-activatable galactoside supramolecular photosensitizers for targeted photodynamic therapy and chemotherapy. J. Control. Release 259, E135–E136 (2017). https://doi.org/10.1016/j.jconrel.2017.03.276
  67. Y. Suzuki, K. Kohno, K. Matsue, A. Sakakibara, E. Ishikawa et al., PD-L1 (SP142) expression in neoplastic cells predicts a poor prognosis for patients with intravascular large B-cell lymphoma treated with rituximab-based multi-agent chemotherapy. Cancer Med. (2020). https://doi.org/10.1002/cam4.3104
  68. M. Michaud, I. Martins, A.Q. Sukkurwala, S. Adjemian, Y. Ma et al., Autophagy-dependent anticancer immune responses induced by chemotherapeutic agents in mice. Science 334, 1573–1577 (2011). https://doi.org/10.1126/science.1208347
  69. C.W. Tseng, C.F. Hung, R.D. Alvarez, C. Trimble, W.K. Huh et al., Pretreatment with cisplatin enhances E7-specific CD8 + T-Cell-mediated antitumor immunity induced by DNA vaccination. Clin. Cancer Res. 14, 3185–3192 (2008). https://doi.org/10.1158/1078-0432.CCR-08-0037
  70. K.N. Kodumudi, K. Woan, D.L. Gilvary, E. Sahakian, S. Wei, J.Y. Djeu, A novel chemoimmunomodulating property of docetaxel: suppression of myeloid-derived suppressor cells in tumor bearers. Clin. Cancer Res. 16, 4583–4594 (2010). https://doi.org/10.1158/1078-0432.CCR-10-0733
  71. Y. Eralp, X. Wang, J.P. Wang, M.F. Maughan, J.M. Polo, L.B. Lachman, Doxorubicin and paclitaxel enhance the antitumor efficacy of vaccines directed against HER2/neu in a murine mammary carcinoma model. Breast Cancer Res. 6, R275–R283 (2004). https://doi.org/10.1186/bcr787
  72. T.J. Haggerty, I.S. Dunn, L.B. Rose, E.E. Newton, S. Martin, J.L. Riley, J.T. Kurnick, Topoisomerase inhibitors modulate expression of melanocytic antigens and enhance T cell recognition of tumor cells. Cancer Immunol. Immun. 60, 133–144 (2011). https://doi.org/10.1007/s00262-010-0926-x
  73. J.W. Hodge, C.T. Garnett, B. Farsaci, C. Palena, K.Y. Tsang, S. Ferrone, S.R. Gameiro, Chemotherapy-induced immunogenic modulation of tumor cells enhances killing by cytotoxic T lymphocytes and is distinct from immunogenic cell death. Int. J. Cancer 133, 624–636 (2013). https://doi.org/10.1002/ijc.28070
  74. H. Ghebeh, C. Lehe, E. Barhoush, K. Al-Romaih, A. Tulbah et al., Doxorubicin downregulates cell surface B7-H1 expression and upregulates its nuclear expression in breast cancer cells: role of B7-H1 as an anti-apoptotic molecule. Breast Cancer Res. 12, R48 (2010). https://doi.org/10.1186/bcr2605
  75. W.J. Lesterhuis, C.J. Punt, S.V. Hato, D. Eleveld-Trancikova, B.J. Jansen et al., Platinum-based drugs disrupt STAT6-mediated suppression of immune responses against cancer in humans and mice. J. Clin. Invest. 121, 3100–3108 (2011). https://doi.org/10.1172/JCI43656
  76. T.J. Lynch, I. Bondarenko, A. Luft, P. Serwatowski, F. Barlesi et al., Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study. J. Clin. Oncol. 30, 2046–2054 (2012). https://doi.org/10.1200/JCO.2011.38.4032
  77. R. Ramakrishnan, D. Assudani, S. Nagaraj, T. Hunter, H.I. Cho, S. Antonia, S. Altiok, E. Celis, D.I. Gabrilovich, Chemotherapy enhances tumor cell susceptibility to CTL-mediated killing during cancer immunotherapy in mice. J. Clin. Invest. 120, 1111–1124 (2010). https://doi.org/10.1172/JCI40269
  78. K. Oleinika, R.J. Nibbs, G.J. Graham, A.R. Fraser, Suppression, subversion and escape: the role of regulatory T cells in cancer progression. Clin. Exp. Immunol. 171, 36–45 (2013). https://doi.org/10.1111/j.1365-2249.2012.04657.x
  79. A. Tanaka, S. Sakaguchi, Regulatory T cells in cancer immunotherapy. Cell Res. 27, 109–118 (2017). https://doi.org/10.1038/cr.2016.151
  80. K. Shitara, H. Nishikawa, Regulatory T cells: a potential target in cancer immunotherapy. Ann. N. Y. Acad. Sci. 1417, 104–115 (2018). https://doi.org/10.1111/nyas.13625
  81. V. Cerullo, I. Diaconu, L. Kangasniemi, M. Rajecki, S. Escutenaire et al., Immunological effects of low-dose cyclophosphamide in cancer patients treated with oncolytic adenovirus. Mol. Ther. 19, 1737–1746 (2011). https://doi.org/10.1038/mt.2011.113
  82. E. Ellebaek, L. Engell-Noerregaard, T.Z. Iversen, T.M. Froesig, S. Munir, S.R. Hadrup, M.H. Andersen, I.M. Svane, Metastatic melanoma patients treated with dendritic cell vaccination, Interleukin-2 and metronomic cyclophosphamide: results from a phase II trial. Cancer Immunol. Immun. 61, 1791–1804 (2012). https://doi.org/10.1007/s00262-012-1242-4
  83. A.K. Nowak, A.M. Cook, A.M. McDonnell, M.J. Millward, J. Creaney et al., A phase 1b clinical trial of the CD40-activating antibody CP-870,893 in combination with cisplatin and pemetrexed in malignant pleural mesothelioma. Ann. Oncol. 26, 2483–2490 (2015). https://doi.org/10.1093/annonc/mdv387
  84. L.E. Kandalaft, D.J. Powell Jr., C.L. Chiang, J. Tanyi et al., Autologous lysate-pulsed dendritic cell vaccination followed by adoptive transfer of vaccine-primed ex vivo co-stimulated T cells in recurrent ovarian cancer. Oncoimmunology 2, e22664 (2013). https://doi.org/10.4161/onci.22664
  85. M. Maio, A.M. Di Giacomo, C. Robert, A.M. Eggermont, Update on the role of ipilimumab in melanoma and first data on new combination therapies. Curr. Opin. Oncol. 25, 166–172 (2013). https://doi.org/10.1097/CCO.0b013e32835dae4f
  86. M.J. Smyth, S.F. Ngiow, A. Ribas, M.W. Teng, Combination cancer immunotherapies tailored to the tumour microenvironment. Nat. Rev. Clin. Oncol 13, 143–158 (2016). https://doi.org/10.1038/nrclinonc.2015.209
  87. G. Middleton, P. Silcocks, T. Cox, J. Valle, J. Wadsley et al., Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): an open-label, randomised, phase 3 trial. Lancet Oncol. 15, 829–840 (2014). https://doi.org/10.1016/S1470-2045(14)70236-0
  88. X. Zang, X. Zhao, H. Hu, M. Qiao, Y. Deng, D. Chen, Nanoparticles for tumor immunotherapy. Eur. J. Pharm. Biopharm. 115, 243–256 (2017). https://doi.org/10.1016/j.ejpb.2017.03.013
  89. Q. Hu, W. Sun, C. Wang, Z. Gu, Recent advances of cocktail chemotherapy by combination drug delivery systems. Adv. Drug Deliv. Rev. 98, 19–34 (2016). https://doi.org/10.1016/j.addr.2015.10.022
  90. D.B. Pacardo, F.S. Ligler, Z. Gu, Programmable nanomedicine: synergistic and sequential drug delivery systems. Nanoscale 7, 3381–3391 (2015). https://doi.org/10.1039/c4nr07677j
  91. R. Langer, N.A. Peppas, Advances in biomaterials, drug delivery, and bionanotechnology. AIChE J. 49, 2990–3006 (2003). https://doi.org/10.1002/aic.690491202
  92. Z. Xie, Y. Su, G.B. Kim, E. Selvi, C. Ma, V. Aragon-Sanabria, J.T. Hsieh, C. Dong, J. Yang, Immune cell-mediated biodegradable theranostic nanoparticles for melanoma targeting and drug delivery. Small (2017). https://doi.org/10.1002/smll.201603121
  93. J.A. Kemp, M.S. Shim, C.Y. Heo, Y.J. Kwon, “Combo” nanomedicine: co-delivery of multi-modal therapeutics for efficient, targeted, and safe cancer therapy. Adv. Drug Deliv. Rev. 98, 3–18 (2016). https://doi.org/10.1016/j.addr.2015.10.019
  94. R.X. Zhang, H.L. Wong, H.Y. Xue, J.Y. Eoh, X.Y. Wu, Nanomedicine of synergistic drug combinations for cancer therapy: strategies and perspectives. J. Control. Release 240, 489–503 (2016). https://doi.org/10.1016/j.jconrel.2016.06.012
  95. R. Kuai, W.M. Yuan, S. Son, J. Nam, J. Xu, Y.C. Fan, A. Schwendeman, J.J. Moon, Elimination of established tumors with nanodisc-based combination chemoimmunotherapy. Sci. Adv. 4, eaao1736 (2018). https://doi.org/10.1126/sciadv.aao1736
  96. M.B. Heo, S.Y. Kim, W.S. Yun, Y.T. Lim, Sequential delivery of an anticancer drug and combined immunomodulatory nanoparticles for efficient chemoimmunotherapy. Int. J. Nanomed. 10, 5981–5993 (2015). https://doi.org/10.2147/Ijn.S90104
  97. Y. Shao, B. Liu, Z. Di, G. Zhang, L.D. Sun, L. Li, C.H. Yan, Engineering of upconverted metal-organic frameworks for near-infrared light-triggered combinational photodynamic/chemo-/immunotherapy against hypoxic tumors. J. Am. Chem. Soc. 142(8), 3939–3946 (2020). https://doi.org/10.1021/jacs.9b12788
  98. F. Zhou, B. Feng, H. Yu, D. Wang, T. Wang, Y. Ma, S. Wang, Y. Li, Tumor microenvironment-activatable prodrug vesicles for nanoenabled cancer chemoimmunotherapy combining immunogenic cell death induction and CD47 blockade. Adv. Mater. 31, e1805888 (2019). https://doi.org/10.1002/adma.201805888
  99. T. Wang, J. Zhang, T. Hou, X. Yin, N. Zhang, Selective targeting of tumor cells and tumor associated macrophages separately by twin-like core-shell nanoparticles for enhanced tumor-localized chemoimmunotherapy. Nanoscale 11, 13934–13946 (2019). https://doi.org/10.1039/c9nr03374b
  100. T.L. ten Hagen, A.L. Seynhaeve, S.T. van Tiel, D.J. Ruiter, A.M. Eggermont, Pegylated liposomal tumor necrosis factor-alpha results in reduced toxicity and synergistic antitumor activity after systemic administration in combination with liposomal doxorubicin (Doxil) in soft tissue sarcoma-bearing rats. Int. J. Cancer 97, 115–120 (2002). https://doi.org/10.1002/ijc.1578
  101. C.L. Guo, Y.A. Chen, W.J. Gao, A.T. Chang, Y.J. Ye et al., Liposomal nanoparticles carrying anti-IL6R antibody to the tumour microenvironment inhibit metastasis in two molecular subtypes of breast cancer mouse models. Theranostics 7, 775–788 (2017). https://doi.org/10.7150/thno.17237
  102. J.J. Wei, Y. Long, R. Guo, X.L. Liu, X. Tang et al., Multifunctional polymeric micelle-based chemo-immunotherapy with immune checkpoint blockade for efficient treatment of orthotopic and metastatic breast cancer. Acta Pharm. Sin. B 9, 819–831 (2019). https://doi.org/10.1016/j.apsb.2019.01.018
  103. B. Zhang, T. Wang, S. Yang, Y. Xiao, Y. Song, N. Zhang, S. Garg, Development and evaluation of oxaliplatin and irinotecan co-loaded liposomes for enhanced colorectal cancer therapy. J. Control. Release 238, 10–21 (2016). https://doi.org/10.1016/j.jconrel.2016.07.022
  104. Z. Gu, Q. Wang, Y. Shi, Y. Huang, J. Zhang, X. Zhang, G. Lin, Nanotechnology-mediated immunochemotherapy combined with docetaxel and PD-L1 antibody increase therapeutic effects and decrease systemic toxicity. J. Control. Release 286, 369–380 (2018). https://doi.org/10.1016/j.jconrel.2018.08.011
  105. Y. Liu, X.G. Chen, P.P. Yang, Z.Y. Qiao, H. Wang, Tumor microenvironmental pH and enzyme dual responsive polymer-liposomes for synergistic treatment of cancer immuno-chemotherapy. Biomacromol 20, 882–892 (2019). https://doi.org/10.1021/acs.biomac.8b01510
  106. J.Q. Lu, X.S. Liu, Y.P. Liao, X. Wang, A. Ahmed, W. Jiang, Y. Ji, H. Meng, A.E. Nel, Breast cancer chemo-immunotherapy through liposomal delivery of an immunogenic cell death stimulus plus interference in the IDO-1 pathway. ACS Nano 12, 11041–11061 (2018). https://doi.org/10.1021/acsnano.8b05189
  107. Z.W. Su, Z.C. Xiao, Y. Wang, J.S. Huang, Y.C. An, X. Wang, X.T. Shuai, Codelivery of anti-PD-1 antibody and paclitaxel with matrix metalloproteinase and pH dual-sensitive micelles for enhanced tumor chemoimmunotherapy. Small 16, 1906832 (2020). https://doi.org/10.1002/Smll.201906832
  108. J. Hernandez-Gil, M. Cobaleda-Siles, A. Zabaleta, L. Salassa, J. Calvo, J.C. Mareque-Rivas, An iron oxide nanocarrier loaded with a Pt(IV) prodrug and immunostimulatory dsRNA for combining complementary cancer killing effects. Adv. Healthc. Mater. 4, 1034–1042 (2015). https://doi.org/10.1002/adhm.201500080
  109. I.H. Lee, S. An, M.K. Yu, H.K. Kwon, S.H. Im, S. Jon, Targeted chemoimmunotherapy using drug-loaded aptamer-dendrimer bioconjugates. J. Control. Release 155, 435–441 (2011). https://doi.org/10.1016/j.jconrel.2011.05.025
  110. C. Xia, S. Yin, S. Xu, G. Ran, M. Deng et al., Low molecular weight heparin-coated and dendrimer-based core-shell nanoplatform with enhanced immune activation and multiple anti-metastatic effects for melanoma treatment. Theranostics 9, 337–354 (2019). https://doi.org/10.7150/thno.29026
  111. S. Shen, H.J. Li, K.G. Chen, Y.C. Wang, X.Z. Yang, Z.X. Lian, J.Z. Du, J. Wang, Spatial targeting of tumor-associated macrophages and tumor cells with a pH-sensitive cluster nanocarrier for cancer chemoimmunotherapy. Nano Lett. 17, 3822–3829 (2017). https://doi.org/10.1021/acs.nanolett.7b01193
  112. W. Ou, J.H. Byeon, R.K. Thapa, S.K. Ku, C.S. Yong, J.O. Kim, Plug-and-play nanorization of coarse black phosphorus for targeted chemo-photoimmunotherapy of colorectal cancer. ACS Nano 12, 10061–10074 (2018). https://doi.org/10.1021/acsnano.8b04658
  113. L. Chen, L.L. Zhou, C.H. Wang, Y. Han, Y.L. Lu et al., Tumor-targeted drug and CpG delivery system for phototherapy and docetaxel-enhanced immunotherapy with polarization toward M1-type macrophages on triple negative breast cancers. Adv. Mater. 31, 1904997 (2019). https://doi.org/10.1002/Adma.201904997
  114. X. Wu, Y. Wu, H. Ye, S. Yu, C. He, X. Chen, Interleukin-15 and cisplatin co-encapsulated thermosensitive polypeptide hydrogels for combined immuno-chemotherapy. J. Control. Release 255, 81–93 (2017). https://doi.org/10.1016/j.jconrel.2017.04.011
  115. X. Dong, A. Yang, Y. Bai, D. Kong, F. Lv, Dual fluorescence imaging-guided programmed delivery of doxorubicin and CpG nanoparticles to modulate tumor microenvironment for effective chemo-immunotherapy. Biomaterials 230, 119659 (2020). https://doi.org/10.1016/j.biomaterials.2019.119659
  116. P. Kadiyala, D. Li, F.M. Nunez, D. Altshuler, R. Doherty et al., High-density lipoprotein-mimicking nanodiscs for chemo-immunotherapy against glioblastoma multiforme. ACS Nano 13, 1365–1384 (2019). https://doi.org/10.1021/acsnano.8b06842
  117. M. Wu, X. Liu, H. Bai, L. Lai, Q. Chen, G. Huang, B. Liu, G. Tang, Surface-layer protein-enhanced immunotherapy based on cell membrane-coated nanoparticles for the effective inhibition of tumor growth and metastasis. ACS Appl. Mater. Interfaces. 11, 9850–9859 (2019). https://doi.org/10.1021/acsami.9b00294
  118. Q. Song, Y. Yin, L. Shang, T. Wu, D. Zhang et al., Tumor microenvironment responsive nanogel for the combinatorial antitumor effect of chemotherapy and immunotherapy. Nano Lett. 17, 6366–6375 (2017). https://doi.org/10.1021/acs.nanolett.7b03186
  119. B.S. Pattni, V.V. Chupin, V.P. Torchilin, New developments in liposomal drug delivery. Chem. Rev. 115, 10938–10966 (2015). https://doi.org/10.1021/acs.chemrev.5b00046
  120. R.K. O’Reilly, C.J. Hawker, K.L. Wooley, Cross-linked block copolymer micelles: functional nanostructures of great potential and versatility. Chem. Soc. Rev. 35, 1068–1083 (2006). https://doi.org/10.1039/b514858h
  121. K. Kataoka, A. Harada, Y. Nagasaki, Block copolymer micelles for drug delivery: design, characterization and biological significance. Adv. Drug Deliv. Rev. 47, 113–131 (2001). https://doi.org/10.1016/s0169-409x(00)00124-1
  122. H.K. Makadia, S.J. Siegel, Poly lactic-co-glycolic acid (PLGA) as biodegradable controlled drug delivery carrier. Polymers 3, 1377–1397 (2011). https://doi.org/10.3390/polym3031377
  123. R. Gref, Y. Minamitake, M.T. Peracchia, V. Trubetskoy, V. Torchilin, R. Langer, Biodegradable long-circulating polymeric nanospheres. Science 263, 1600–1603 (1994). https://doi.org/10.1126/science.8128245
  124. Y.K. Luu, K. Kim, B.S. Hsiao, B. Chu, M. Hadjiargyrou, Development of a nanostructured DNA delivery scaffold via electrospinning of PLGA and PLA-PEG block copolymers. J. Control. Release 89, 341–353 (2003). https://doi.org/10.1016/s0168-3659(03)00097-x
  125. J. Zimmermann, N. Jurgensen, A.J. Morfa, B.H. Wang, S. Tekoglu, G. Hernandez-Sosa, Poly(lactic-co-glycolic acid) (PLGA) as ion-conducting polymer for biodegradable light-emitting electrochemical cells. ACS Sustain. Chem. Eng. 4, 7050–7055 (2016). https://doi.org/10.1021/acssuschemeng.6b01953
  126. N. Rapoport, Physical stimuli-responsive polymeric micelles for anti-cancer drug delivery. Prog. Polym. Sci. 32, 962–990 (2007). https://doi.org/10.1016/j.progpolymsci.2007.05.009
  127. T.Y. Kim, D.W. Kim, J.Y. Chung, S.G. Shin, S.C. Kim et al., Phase I and pharmacokinetic study of Genexol-PM, a cremophor-free, polymeric micelle-formulated paclitaxel, in patients with advanced malignancies. Clin. Cancer Res. 10, 3708–3716 (2004). https://doi.org/10.1158/1078-0432.Ccr-03-0655
  128. X.J. Chen, X.Q. Zhang, M.X. Tang, Q. Liu, G. Zhou, Anti-PD-L1-modified and ATRA-loaded nanoparticles for immuno-treatment of oral dysplasia and oral squamous cell carcinoma. Nanomedicine 15, 951–968 (2020). https://doi.org/10.2217/nnm-2019-0397
  129. L.L. Dai, X. Li, M.J. Yao, P.Y. Niu, X.C. Yuan et al., Programmable prodrug micelle with size-shrinkage and charge-reversal for chemotherapy-improved IDO immunotherapy. Biomaterials 241, 119901 (2020). https://doi.org/10.1016/j.biomaterials.2020.119901
  130. E. Perez-Herrero, A. Fernandez-Medarde, Advanced targeted therapies in cancer: drug nanocarriers, the future of chemotherapy. Eur. J. Pharm. Biopharm. 93, 52–79 (2015). https://doi.org/10.1016/j.ejpb.2015.03.018
  131. H.J. Hsu, J. Bugno, S.R. Lee, S. Hong, Dendrimer-based nanocarriers: a versatile platform for drug delivery. Wires Nanomed. Nanobi. 9, e1409 (2017). https://doi.org/10.1002/Wnan.1409
  132. H.J. Li, J.Z. Du, X.J. Du, C.F. Xu, C.Y. Sun et al., Stimuli-responsive clustered nanoparticles for improved tumor penetration and therapeutic efficacy. Proc. Natl. Acad. Sci. U.S.A. 113, 4164–4169 (2016). https://doi.org/10.1073/pnas.1522080113
  133. J.P. Yang, Q. Zhang, H. Chang, Y.Y. Cheng, Surface-engineered dendrimers in gene delivery. Chem. Rev. 115, 5274–5300 (2015). https://doi.org/10.1021/cr500542t
  134. T.A. Gilewski, G. Ragupathi, M. Dickler, S. Powell, S. Bhuta et al., Immunization of high-risk breast cancer patients with clustered sTn-KLH conjugate plus the immunologic adjuvant QS-21. Clin. Cancer Res. 13, 2977–2985 (2007). https://doi.org/10.1158/1078-0432.CCR-06-2189
  135. S.F. Slovin, G. Ragupathi, C. Musselli, K. Olkiewicz, D. Verbel et al., Fully synthetic carbohydrate-based vaccines in biochemically relapsed prostate cancer: clinical trial results with alpha-N-acetylgalactosamine-O-serine/threonine conjugate vaccine. J. Clin. Oncol. 21, 4292–4298 (2003). https://doi.org/10.1200/Jco.2003.04.112
  136. L.M. Krug, G. Ragupathi, C. Hood, M.G. Kris, V.A. Miller et al., Vaccination of patients with small-cell lung cancer with synthetic fucosyl GM-1 conjugated to keyhole limpet hemocyanin. Clin. Cancer Res. 10, 6094–6100 (2004). https://doi.org/10.1158/1078-0432.Ccr-04-0482
  137. T. Lang, Y. Liu, Z. Zheng, W. Ran, Y. Zhai, Q. Yin, P. Zhang, Y. Li, Cocktail strategy based on spatio-temporally controlled nano device improves therapy of breast cancer. Adv. Mater. 31, e1903844 (2019). https://doi.org/10.1002/adma.201903844
  138. H.J. Li, J.Z. Du, J. Liu, X.J. Du, S. Shen et al., Smart superstructures with ultrahigh pH-sensitivity for targeting acidic tumor microenvironment: instantaneous size switching and improved tumor penetration. ACS Nano 10, 6753–6761 (2016). https://doi.org/10.1021/acsnano.6b02326
  139. T. Jiang, W. Sun, Q. Zhu, N.A. Burns, S.A. Khan, R. Mo, Z. Gu, Furin-mediated sequential delivery of anticancer cytokine and small-molecule drug shuttled by graphene. Adv. Mater. 27, 1021–1028 (2015). https://doi.org/10.1002/adma.201404498
  140. X.X. Hu, Y. Wang, B. Peng, Chitosan-capped mesoporous silica nanoparticles as pH-responsive nanocarriers for controlled drug release. Chem. Asian J. 9, 319–327 (2014). https://doi.org/10.1002/asia.201301105
  141. I.I. Slowing, J.L. Vivero-Escoto, C.W. Wu, V.S.Y. Lin, Mesoporous silica nanoparticles as controlled release drug delivery and gene transfection carriers. Adv. Drug Deliv. Rev. 60, 1278–1288 (2008). https://doi.org/10.1016/j.addr.2008.03.012
  142. Q.S. Zheng, T.R. Lin, H.Y. Wu, L.Q. Guo, P.R. Ye et al., Mussel-inspired polydopamine coated mesoporous silica nanoparticles as pH-sensitive nanocarriers for controlled release. Int. J. Pharmaceut. 463, 22–26 (2014). https://doi.org/10.1016/j.ijpharm.2013.12.045
  143. D.W. Zheng, J.L. Chen, J.Y. Zhu, L. Rong, B. Li et al., Highly integrated nano-platform for breaking the barrier between chemotherapy and immunotherapy. Nano Lett. 16, 4341–4347 (2016). https://doi.org/10.1021/acs.nanolett.6b01432
  144. D. Bobo, K.J. Robinson, J. Islam, K.J. Thurecht, S.R. Corrie, Nanoparticle-based medicines: a review of FDA-approved materials and clinical trials to date. Pharm. Res. 33, 2373–2387 (2016). https://doi.org/10.1007/s11095-016-1958-5
  145. X. Liang, X. Ye, C. Wang, C. Xing, Q. Miao et al., Photothermal cancer immunotherapy by erythrocyte membrane-coated black phosphorus formulation. J. Control. Release 296, 150–161 (2019). https://doi.org/10.1016/j.jconrel.2019.01.027
  146. J. Shao, H. Xie, H. Huang, Z. Li, Z. Sun et al., Biodegradable black phosphorus-based nanospheres for in vivo photothermal cancer therapy. Nat. Commun. 7, 12967 (2016). https://doi.org/10.1038/ncomms12967
  147. W. Chen, J. Ouyang, H. Liu, M. Chen, K. Zeng et al., Black phosphorus nanosheet-based drug delivery system for synergistic photodynamic/photothermal/chemotherapy of cancer. Adv. Mater. 29, 1603864 (2017). https://doi.org/10.1002/adma.201603864
  148. M. Nishikawa, Y. Mizuno, K. Mohri, N. Matsuoka, S. Rattanakiat, Y. Takahashi, H. Funabashi, D. Luo, Y. Takakura, Biodegradable CpG DNA hydrogels for sustained delivery of doxorubicin and immunostimulatory signals in tumor-bearing mice. Biomaterials 32, 488–494 (2011). https://doi.org/10.1016/j.biomaterials.2010.09.013
  149. Y.K. Li, M. Fang, J. Zhang, J. Wang, Y. Song et al., Hydrogel dual delivered celecoxib and anti-PD-1 synergistically improve antitumor immunity. Oncoimmunology 5, 1074374 (2016). https://doi.org/10.1080/2162402X.2015.1074374
  150. H. Qiao, X. Chen, E. Chen, J. Zhang, D. Huang et al., Folated pH-degradable nanogels for the simultaneous delivery of docetaxel and an IDO1-inhibitor in enhancing cancer chemo-immunotherapy. Biomater. Sci. 7, 2749–2758 (2019). https://doi.org/10.1039/c9bm00324j
  151. Q. Lv, C.L. He, F.L. Quan, S.J. Yu, X.S. Chen, DOX/IL-2/IFN-gamma co-loaded thermo-sensitive polypeptide hydrogel for efficient melanoma treatment. Bioact. Mater. 3, 118–128 (2018). https://doi.org/10.1016/j.bioactmat.2017.08.003
  152. H. Jin, C. Wan, Z. Zou, G. Zhao, L. Zhang et al., Tumor ablation and therapeutic immunity induction by an injectable peptide hydrogel. ACS Nano 12, 3295–3310 (2018). https://doi.org/10.1021/acsnano.7b08148
  153. P.F. Zhao, Y.H. Wang, X.J. Kang, A.H. Wu, W.M. Yin et al., Dual-targeting biomimetic delivery for anti-glioma activity via remodeling the tumor microenvironment and directing macrophagemediated immunotherapy. Chem. Sci. 9, 2674–2689 (2018). https://doi.org/10.1039/c7sc04853j
  154. H. Wang, Y. Tang, Y. Fang, M. Zhang, H. Wang, Z. He, B. Wang, Q. Xu, Y. Huang, Reprogramming tumor immune microenvironment (TIME) and metabolism via biomimetic targeting codelivery of shikonin/JQ1. Nano Lett. 19, 2935–2944 (2019). https://doi.org/10.1021/acs.nanolett.9b00021
  155. V. Vijayan, S. Uthaman, I.K. Park, Cell membrane-camouflaged nanoparticles: a promising biomimetic strategy for cancer theragnostics. Polymers 10, 1009098 (2018). https://doi.org/10.3390/polym10090983
  156. H. Wang, Y. Liu, R. He, D. Xu, J. Zang, N. Weeranoppanant, H. Dong, Y. Li, Cell membrane biomimetic nanoparticles for inflammation and cancer targeting in drug delivery. Biomater. Sci. 8, 552–568 (2020). https://doi.org/10.1039/c9bm01392j
  157. D. Dehaini, R.H. Fang, L. Zhang, Biomimetic strategies for targeted nanoparticle delivery. Bioeng. Transl. Med. 1, 30–46 (2016). https://doi.org/10.1002/btm2.10004
  158. R.H. Fang, A.V. Kroll, W. Gao, L. Zhang, Cell membrane coating nanotechnology. Adv. Mater. 30, e1706759 (2018). https://doi.org/10.1002/adma.201706759
  159. Y. Liu, J. Luo, X. Chen, W. Liu, T. Chen, Cell membrane coating technology: a promising strategy for biomedical applications. Nano-Micro Lett. 11, 100 (2019). https://doi.org/10.1007/s40820-019-0330-9
  160. W. Du, C. Chen, P. Sun, S. Zhang, J. Zhang et al., Eliciting an immune hot tumor niche with biomimetic drug-based multi-functional nanohybrids augments immune checkpoint blockade-based breast cancer therapy. Nanoscale 12, 3317–3329 (2020). https://doi.org/10.1039/c9nr09835f
  161. E. Lasalvia-Prisco, P. Goldschmidt, F. Galmarini, S. Cucchi, J. Vazquez et al., Addition of an induction regimen of antiangiogenesis and antitumor immunity to standard chemotherapy improves survival in advanced malignancies. Med. Oncol. 29, 3626–3633 (2012). https://doi.org/10.1007/s12032-012-0301-1
  162. I. Liikanen, L. Ahtiainen, M.L. Hirvinen, S. Bramante, V. Cerullo et al., Oncolytic adenovirus with temozolomide induces autophagy and antitumor immune responses in cancer patients. Mol. Ther. 21, 1212–1223 (2013). https://doi.org/10.1038/mt.2013.51
  163. B. Ding, X. Wu, W. Fan, Z. Wu, J. Gao et al., Anti-DR5 monoclonal antibody-mediated DTIC-loaded nanoparticles combining chemotherapy and immunotherapy for malignant melanoma: target formulation development and in vitro anticancer activity. Int. J. Nanomed. 6, 1991–2005 (2011). https://doi.org/10.2147/IJN.S24094
  164. B.Y. Ding, W. Zhang, X. Wu, J. Wang, C. Xie et al., DR5 mAb-conjugated, DTIC-loaded immuno-nanoparticles effectively and specifically kill malignant melanoma cells in vivo. Oncotarget 7, 57160–57170 (2016). https://doi.org/10.18632/oncotarget.11014
Read More
Author biographies are not available.
Download this PDF file
PDF
Statistic
Read Counter : 9686 Download : 7340

Most read articles by the same author(s)